|
|
 |
Burke Internal Medicine, Inc.
Primary Care & Clinical Research
We have a clinical research center as part of our medical practice in Burke, Virginia. Free medical care is a benefit of clinical study participation. Current and past research studies are listed below.
All study visits are conducted at our office in Burke, Virginia, near Fairfax in Northern Virginia. Please contact us for more information or to enroll.
Current Clinical Studies Opportunities
We are currently accepting subjects for all of the below clinical research studies. Participants receive free medical evaluations, free laboratory testings and free medications.
Jupiter Heart Disease Prevention Study: A heart disease prevention trial for men 50 years old or above and women 60 years or above with normal cholesterol.
Diabetes and High Cholesterol Study: For anyone who is between 18 and 75 years old with type II diabetes which is controlled by diet and exercise or oral medications and has high cholesterol.
Respiratory Tract Infections Study: Adults with acute exacerbation of chronic bronchitis or pneumonia receive free approved antibiotic therapy for their infection.
Chronic Renal Failure Diabetes and Anemia (TREAT STUDY): Qalified patients will receive free medications and follow up on their anemia.
Insulin Study: A new long-acting insulin with less effect on weight gain and more stable levels in the body. Anyone who is on insulin may be qualified to receive glucometer and test strips, insulin (levelin), and free doctor's evaluations and lab tests.
Clinical Research Experience
Prior studies (Completed or On-Going but not enrolling):
- INVEST Trial (University of Florida). An international, randomized, controlled clinical trial comparing a c calcium antagonist treatment strategy (verapamil SR) with a non-calcium antagonist treatment strategy (atenolol) for control of hypertension in a primary care coronary artery disease patient population. Sponsor: Knoll AG BASF Pharma. Six patients enrolled. (2000-2002).
- IRIS Trial (AstraZeneca). A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in South Asian Subjects. Eleven patients enrolled. (2003-2005)
- STARSHIP STUDY (AstraZeneca). A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects. Nine patients enrolled. (2003-2005)
- B3A20005 (GlaxoSmithKline). A 12-Week, Parallel-Group, Double-Bline, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of GW427353B at 10mg, 25mg, 50mg and 100mg, Administered Orally, Once Daily, as Monotherapy in Subjects with Type 2 Diabetes Mellitus. Ten patients enrolled. (2004-2005)
- SB-275833/030-Studies 030A and 030B (GlaxoSmithKline). Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB275833, Applied Twice Daily, versus Oral Cephalexin, 500 mg in Adults, or 12.5 mg/kg (250mg/5ml) in Children, Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions. Seventeen patients enrolled. (2004-2005)
- 20040180 (Amgen). An Open-Label, Single-Arm Study to Assess the safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease (Dec 2004-Present)
- D6160C00029 Gallant 5 (AstraZeneca). A 52-Week Randomized, Double Blind, Parallel-Group, Multi-Centre, Active Controlled (Metformin) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes. (Mar 2005-Present)
- DPB 100925 (GlaxoSmithKline). A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg, 45mg), Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension. (Apr 2005-Present)
- CS8663-A-U301 (Sankyo). A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of Co-Administration of Olmesartan Medoxomil plus Amlodipine Compared to Monotherapy in Patients with Mild to Severe Hypertension. (Apr 2005-Present)
|
